.png){kind=icon}
.png){kind=icon}
Return
Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial
.png){kind=icon}
OA
AI
D
T
A
Y
A
DOI：10.1007/s11102-026-01733-2.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To evaluate the hypothesis that breakthrough acromegaly symptom exacerbation frequency would be reduced after switching biochemically controlled patients from depot somatostatin receptor ligand (SRL) injections to once-daily oral paltusotine. Biochemical disease control (insulin-like growth factor 1 [IGF-I]) and Acromegaly Symptom Diary (ASD) data were analyzed from PATHFNDR-1, a 36-week, randomized, placebo-controlled, double-blind, phase 3 trial of paltusotine in patients with acromegaly biochemically controlled (IGF-I ≤ 1.0× ULN) with SRLs. The ASD measured the daily severity of 7 core and 2 exploratory acromegaly symptoms, each rated on a scale from 0 to 10 based on 24-hour recall. Breakthrough acromegaly symptom exacerbations were defined as ≥ 2-point increases for any individual symptom score, comparing a 2-day average with the prior 2-day average. Despite no significant changes in IGF-I levels or overall core symptom severity scores, mean (SE) symptom exacerbation frequencies declined progressively after switching to paltusotine, from 30.2% (5.6%) of days during screening (SRL treatment) to 6.2% (1.6%) of days (n = 22, p < 0.0001). The reduction in individual symptom exacerbation frequencies with paltusotine treatment was consistent across all acromegaly symptoms assessed. IGF-I levels did not correlate significantly with symptom severity scores or symptom variability. In patients with acromegaly biochemically controlled with injected SRLs, switching to once-daily oral paltusotine was associated with stable biochemical control, stable symptom severity, and a significantly reduced frequency of symptom exacerbations. A simple daily symptom assessment tool provided important information pertaining to acromegaly disease control that was not apparent from IGF-I measurements.
Keywords:
Acromegaly
Insulin-like growth factor 1
Patient-reported outcomes
Somatostatin/analogs and derivatives
Symptom exacerbation
Symptom evaluation
Journal
IF:
3.4
Papers:
1.7K
Citations:
3.6K
Organization
Cited Papers